Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc demonstrates a strong outlook due to its focused mission on addressing critical treatment gaps in osteosarcoma, supported by impressive preliminary survival data for its lead product, OST-HER2, in resected pulmonary metastatic cases. The company is well-positioned to capture a significant portion of the rapidly expanding veterinary oncology market, projected to grow from $1.58 billion in 2024 to $4.77 billion by 2034, reflecting sustained demand for targeted therapies. Furthermore, successful discussions with potential investors and regulatory specialists indicate robust momentum towards establishing a dedicated animal-health entity, enhancing OS Therapies' operational capabilities and market presence.

Bears say

OS Therapies Inc. recorded a substantial net operating loss of $6.9 million for the third quarter of 2025, amounting to $0.21 per share, which raises concerns about the company's financial sustainability amidst ongoing high expenditures. The continued investment in its listeria-based cancer immunotherapy programs, including OST-HER2, indicates a strategic focus on research and development, but such spending without revenue generation may hinder short-term financial stability. Additionally, operating at a net loss suggests challenges in achieving profitability in the near future, casting a shadow on potential investor sentiment towards the stock.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.